Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

PHASE3CompletedINTERVENTIONAL
Enrollment

595

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

October 31, 2008

Conditions
DepressionDepressive DisorderDepressive Disorder, Major
Interventions
DRUG

Desvenlafaxine succinate sustained-release (DVS SR)

flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.

DRUG

Escitalopram

Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.

Trial Locations (70)

1062

Buenos Aires

1119

Buenos Aires

1126

Buenos Aires

1205

Buenos Aires

1221

Buenos Aires

1414

Buenos Aires

1425

Buenos Aires

1900

La Plata

5500

Mendoza

10032

New York

10128

New York

10523

Elmsford

11423

Hollis

13210

Syracuse

15206

Pittsburgh

15213

Pittsburgh

19104

Philadelphia

21208

Baltimore

22903

Charlottesville

23230

Richmond

26506

Morgantown

27612

Raleigh

29201

Columbia

29407

Charleston

29464

Mt. Pleasant

30076

Roswell

30328

Atlanta

32607

Gainesville

32751

Maitland

33065

Coral Springs

33912

Fort Myers

34613

Brooksville

38117

Memphis

53562

Middleton

55101

Saint Paul

60093

Northfield

60523

Oak Brook

66211

Overland Park

67214

Wichita

70115

New Orleans

71130

Shreveport

73103

Oklahoma City

75235

Dallas

76201

Denton

77090

Houston

77401

Bellaire

80212

Denver

85381

Peoria

89106

Las Vegas

91107

Pasadena

92103

San Diego

92108

San Diego

06416

Cromwell

06030

Farmington

06708

Waterbury

02114

Boston

02721

Fall River

08854

Piscataway

02914

East Providence

02865

Lincoln

05401

Burlington

Unknown

Santiago

Barranquilla

Bogotá

Bucamaranga

Mexico City

Monterrey

Tobasco

Chiclayo

Lima

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00406640 - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women | Biotech Hunter | Biotech Hunter